Clinical Trial Update: Maintenance Obinutuzumab in Treating Patients With Central Nervous System Lymphoma Who Have Achieved a Complete or Partial Response [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating maintenance obinutuzumab in patients with primary central nervous system lymphoma who have achieved a complete or partial response; the…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Central Nervous System Lymphoma

Drugs mentioned

• Obinutuzumab (obinutuzumab)

Snippet

Sponsor: Providence Health & Services | Conditions: Primary Central Nervous System Lymphoma | Phase 2 | Status: RECRUITING